Clinical trials: Dementia Disorders
Parkinson's Disease Dementia
To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
This is a randomized, double blinded, placebo-controlled Phase II study to investigate the efficacy and safety of ceftriaxone in patients with mild to moderate Parkinson's disease dementia (PDD).This study will enroll…
- Trial name
- NCT03413384
- Testing
- Ceftriaxone
- Where
- 6 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- BrainX Corporation
Alzheimer Disease
A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients
The purpose of this study is to evaluate efficacy and safety of Choline alfoscerate and Donepezil for cognitive improvements of patients with cerebrovascular injury in Alzheimer patients
- Trial name
- NCT02648906
- Testing
- Choline alfoscerate
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Alzheimer Disease
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
This randomised, double-blinded, placebo-controlled study aims to establish metabolic improvements in subjects diagnosed with Alzheimer's Disease (AD) by treatment with CMA2 including N-acetyl-L-cysteine (NAC)…
- Trial name
- COGNIS (NCT07062198)
- Testing
- Combined metabolic activators, Collagen and maltodextrin
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 845 people
- Sponsor
- ScandiBio Therapeutics AB
Alzheimer Disease, Early Onset
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
- Trial name
- NCT06750432
- Testing
- PMN310
- Where
- 22 sites in United States
- Volunteers
- 144 people
- Sponsor
- ProMis Neurosciences, Inc
Chorea
First Time Use of SD-809 in Huntington Disease
The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.
- Trial name
- First-HD (NCT01795859)
- Testing
- SD-809
- Where
- 43 sites in United States, Australia and 1 more
- Volunteers
- 90 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls
This is an experimental medicine study to evaluate the kinetics of cerebrospinal fluid (CSF) biomarkers in subjects with Alzheimer's disease (AD) or progressive supranuclear palsy (PSP) compared to healthy controls using a heavy…
- Trial name
- NCT01348061
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- KineMed
Alzheimer Disease, Dementia
A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
This is a bridging study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with Alzheimer disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05527288
- Testing
- Drug: [18F]florbetaben
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Dementia With Lewy Bodies, REM Sleep Behavior Disorder
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia…
- Conditions
- Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
- Trial name
- NCT02708186
- Testing
- Nelotanserin
- Where
- 23 sites in United States
- Volunteers
- 34 people
- Sponsor
- Axovant Sciences Ltd.
Alzheimer Disease
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with Alzheimer's disease.
- Trial name
- NCT00956410
- Testing
- CAD106
- Where
- 4 sites in France, Sweden and 2 more
- Volunteers
- 21 people
- Sponsor
- Novartis
Dementia Associated With Cerebrovascular Disease
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
The primary objectives are to confirm that donepezil hydrochloride has superior efficacy compared with placebo in improving cognitive function, as measured by Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog)…
- Trial name
- NCT02660983
- Testing
- Donepezil hydrochloride
- Where
- 31 sites in South Korea
- Volunteers
- 302 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer's Disease
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm^2 in patients with probable Alzheimer's Disease (Mini-Mental State…
- Trial name
- EXTRA (NCT00622713)
- Testing
- Rivastigmine transdermal patch
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Novartis
Huntington Disease
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
- Trial name
- NCT06826612
- Testing
- SPK-10001
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
- Trial name
- NCT04079803
- Testing
- Simufilam 100 mg tablet, Simufilam 50 mg oral tablet
- Where
- 9 sites in United States
- Volunteers
- 64 people
- Sponsor
- Cassava Sciences, Inc.
Dementia, Alzheimer Disease
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
The purpose of the study is to compare the safety and efficacy of risperidone (an antipsychotic medication) to that of placebo in the treatment of behavioral disturbances associated with dementia.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular
- Trial name
- NCT00249145
- Testing
- risperidone
- Volunteers
- 349 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Alzheimer's Disease
A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the long-term safety, tolerability and antibody response of Lu AF20513 in patients with Alzheimer's disease who have completed the 16026A study.
- Trial name
- NCT03668405
- Testing
- Lu AF20513
- Where
- 4 sites in Finland, Sweden
- Volunteers
- 18 people
- Sponsor
- H. Lundbeck A/S
Vascular Dementia
The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule
As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD).
- Trial name
- NCT01978730
- Testing
- high dose group of SaiLuoTong capsule, low dose group of SaiLuoTong, the control group
- Where
- 16 sites in China
- Volunteers
- 372 people
- Sponsor
- Shineway Pharmaceutical Co.,Ltd
Alzheimer Disease
Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease (AD)
This is a prospective open comprehensive proof-of-principle pilot study.
- Trial name
- NCT04333329
- Testing
- NEUROLITH
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Storz Medical AG
Alzheimer Disease, Alzheimer Disease (AD)
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention
- Trial name
- NCT06831812
- Testing
- AV-1959R (Abeta vaccine)
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Alzheimer Disease, Early Onset
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants…
- Trial name
- NCT07328451
- Testing
- DNL628
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Denali Therapeutics Inc.
Agitation, Alzheimer's Disease
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
The objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in participants with Alzheimer's Disease (AD).
- Trial name
- NCT01584440
- Testing
- AVP-923-20, AVP-923-30
- Where
- 44 sites in United States
- Volunteers
- 220 people
- Sponsor
- Avanir Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.